Clozapine antagonizes the induction of striatal Fos expression by typical neuroleptics

European Journal of Pharmacology

Volumn 358, Issue 3, 1998, Pages

  Wirtshafter, David ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Atypical neuroleptic; c Fos; Striatum

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; IMMEDIATE EARLY GENE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032500804     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00652-9     Document Type: Article

References (8)

1. Ashby, C.R., Wang, R.Y., 1996. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349-394.
2. Gerfen, C.R., Kitai, S.T., 1997. Intrastriatal administration of the muscarinic antagonist scopolamine: effects on D2 dopamine receptor antagonist-induced behavior and gene expression in striatal neurons. Soc. Neurosci. Abstr. 23, 745.
3. Guo, N., Robertson, G.S., Fibiger, H.C., 1992. Scopolamine attenuates haloperidol-induced c-fos expression in the striatum. Brain Res. 588, 164-167.
4. Haracz, J.L., Tschanz, J.T., Wang, Z., White, I.M., Rebec, G.V., 1993. Striatal single-unit responses to amphetamine and neuroleptics in freely moving rats. Neurosci. Biobehav. Rev. 17, 1-12.
5. MacGibbon, G.A., Lawlor, P.A., Hughes, P., Young, D., Dragunow, M., 1995. Differential expression of inducible transcription factors in basal ganglia neurons. Mol. Brain Res. 34, 294-302.
6. 3 receptors. Mol. Pharmacol. 43, 749-754.
7. Robertson, G.S., Fibiger, H.C., 1992. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328.
8. Sayers, A.C., Burki, H.R., Ruch, W., Asper, H., 1976. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacology 51, 15-22.